Subscribe To
INAB / IN8bio, Inc. (INAB) Is Up 37.87% in One Week: What You Should Know
INAB News
By GlobeNewsWire
November 2, 2023
IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta more_horizontal
By Zacks Investment Research
June 5, 2023
IN8bio, Inc. (INAB)'s Technical Outlook is Bright After Key Golden Cross
IN8bio, Inc. (INAB) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, INAB's 50-day more_horizontal
By Zacks Investment Research
May 24, 2023
IN8bio, Inc. (INAB) Is Up 37.87% in One Week: What You Should Know
Does IN8bio, Inc. (INAB) have what it takes to be a top stock pick for momentum investors? Let's find out. more_horizontal
By PennyStocks
May 2, 2023
Stock Market Today: Penny Stocks To Watch Amid Banking Crisis
Penny stocks to watch as bank stocks fall in the stock market today. The post Stock Market Today: Penny Stocks To Watch Amid Banking Crisis appeared f more_horizontal
By InvestorPlace
April 26, 2023
Why Is IN8bio (INAB) Stock Up 9% Today?
IN8bio (NASDAQ: INAB ) stock is rising higher on Wednesday as the company's shares continue their wild swings this week. The strong movement for the s more_horizontal
By Proactive Investors
April 25, 2023
IN8bio stock price falls even as company receives FDA orphan drug status for brain cancer treatment
IN8bio (NASDAQ:INAB), Inc shares slid 16% to $2.51 in early Tuesday trading after the biopharmaceutical company announced that it has received orphan more_horizontal
By InvestorPlace
April 25, 2023
What Is Going on With In8bio (INAB) Stock Today?
In8bio (NASDAQ: INAB ) stock is on the move Tuesday as investors react to a recent rally and additional news from the biotechnology company. First off more_horizontal
By GlobeNewsWire
April 11, 2023
IN8bio to Present New Positive Clinical Data from Phase 1 Trial of INB-100 at EBMT 2023 Annual Meeting
NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innova more_horizontal